Vitrolife ABOSTO:VITR +2.62%79 Market Cap is kr12,454 Mil as of Jul. 03, 2026. GuruFocus rates OSTO:VITR with a GF Score™ of 79/100 and a GF Value™ of kr162.22 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Vitrolife AB ranks better than 82.26% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vitrolife AB's share price for the quarter that ended in Mar. 2026 was kr94.25. Vitrolife AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 135 Mil. Therefore, Vitrolife AB's market cap for the quarter that ended in Mar. 2026 was kr12,766 Mil.
Vitrolife AB's quarterly market cap
increased
from Sep. 2025 (kr17,567 Mil) to Dec. 2025 (kr18,556 Mil) but then
declined
from Dec. 2025 (kr18,556 Mil) to Mar. 2026 (kr12,766 Mil).
Vitrolife AB's annual market cap
increased
from Dec. 2023 (kr26,372 Mil) to Dec. 2024 (kr29,121 Mil) but then
declined
from Dec. 2024 (kr29,121 Mil) to Dec. 2025 (kr18,556 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vitrolife AB's Enterprise Value for Today is kr13,152 Mil.
Vitrolife AB (OSTO:VITR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vitrolife AB Market Cap Related Terms
Vitrolife AB Market Cap Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vitrolife AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vitrolife AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (OSTO:VITR) has a Market Cap of kr12,454 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vitrolife AB and its competitors. According to the industry distribution chart, Vitrolife AB ranks #154 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 17.7%.
Is Vitrolife AB's Market Cap too high?
Vitrolife AB's current Market Cap is kr12,454 Mil. Based on the distribution chart, Vitrolife AB ranks #154 out of 868 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #154 out of 868 companies for Market Cap. This places Vitrolife AB in the top 18% of its industry — outperforming the majority of peers. The industry median Market Cap is 122.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 122.08, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 122.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Market Cap is kr12,454 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.22, compared to a current price of kr91.95 — trading 43.3% below its estimated fair value. The current Market Cap is kr12,454 Mil. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current Market Cap is kr12,454 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr91.95 is trading 43.3% below its estimated GF Value™ of kr162.22.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
Market Cap: kr12,454 Mil
GF Value™: kr162.22 vs. price of kr91.95 (43.3% below fair value)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score
Get the complete analysis for OSTO:VITR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
